Rheumatology key messagesRF and ACPA are prognostic factors that predict progressive bone erosion in RA patients.Denosumab effectively prevents bone erosion progression in patients receiving MTX with these risk factors.Denosumab is expected to show reliable efficacy in patients with extensive erosion progression.

Introduction
============

RA is a chronic disease characterized by persistent synovitis, systemic inflammation and joint destruction \[[@key416-B1]\]. One of the causes of bone erosion and bone loss is increased osteoclast activity \[[@key416-B2]\]. M-CSF and receptor activator of nuclear factor kB (RANK) ligand (RANKL) are considered to be essential for osteoclast differentiation, activation and survival \[[@key416-B3]\]. Denosumab is a fully human mAb that binds specifically to human RANKL and inhibits bone resorption \[[@key416-B8]\]; thus, it is expected to prevent the progression of bone erosion and bone loss.

We previously reported the efficacy of denosumab with regard to the inhibition of bone erosion among Japanese RA patients in the dose-response study of Denosumab in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE study), which was a 12-month, multicentre, randomized, double-blind, placebo-controlled, phase II study of denosumab administered subcutaneously at a dosage of 60 mg every 6 months (Q6M), 3 months (Q3M) or 2 months (Q2M) with MTX \[[@key416-B9]\]. The results indicated that denosumab inhibited the progression of bone erosion. However, differences in the treatment response according to subgroups based on the bone erosion progression risk factor status have not been reported. Previous studies have reported that poor prognostic factors, such as RF and ACPA, are risk factors for the progression of radiographic erosion in RA patients \[[@key416-B10], [@key416-B11]\]. In the present study, we focused on the results of subgroups that had poor prognostic factors in the DRIVE study. We grouped patients according to the swollen joint count (SJC) and CRP level, in addition to RF and ACPA, because these have been reported as risk factors for bone destruction \[[@key416-B12]\]. The primary objective of this subgroup analysis was to evaluate the effect of denosumab on bone erosion progression among RA patients in risk factor subgroups.

Methods
=======

Patients and study design
-------------------------

The eligibility criteria and design of this study have been described in detail in our previous report \[[@key416-B9]\]. It is important to note that, at registration, we excluded patients who were orally administered Bisphosphonates (BPs) for a total of 2 years (104 weeks) or more in the past, as well as patients who were intravenously administered BPs in the past.

Patients were randomly registered under a double-blind design to subcutaneously receive either placebo or denosumab 60 mg Q6M, Q3M or Q2M. Randomization was stratified according to glucocorticoid use and RF status at baseline. All patients basically continued MTX treatment (6--16 mg/week) with vitamin D ⩾400 IU and calcium ⩾600 mg/day. The investigators were allowed to prescribe bucillamine, salazosulfapyridine, glucocorticoid and/or NSAIDs at any time throughout the study. Patient eligibility depended on a diagnosis of RA by the investigator and fulfilment of the 1987 American College of Rheumatology (ACR) criteria \[[@key416-B15]\], with RA disease duration of 6 months to \<5 years and at least 6 swollen joints among a total of 58 joints assessed by the investigator at screening. For enrolment, patients also had to demonstrate radiographic bone erosion as assessed by the investigator or meet the following criteria at screening: CRP level ⩾1.0 mg/dl or ESR ⩾28 mm/h, and ACPA positivity or RF level \>20 IU/ml. The main exclusion criterion was previous or current use of biologics for the treatment of RA. The use of bisphosphonates and oral glucocorticoids at a dose of \>10 mg/day (prednisolone equivalent) was prohibited throughout the study.

This study was approved by the institutional review board of each participating institution and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.

Radiographic assessment
-----------------------

Radiographs of the hands, wrists and feet, obtained at baseline and at 6 and 12 months, were assessed according to the van der Heijde modified Sharp method \[[@key416-B16]\]. Two well-trained readers who were blinded to the treatment groups, patient characteristics and time order evaluated the images. The average scores of the two readers were used for analyses. The changes in the modified Sharp erosion score from baseline were calculated at 6 and 12 months.

Statistical analysis
--------------------

Changes in the erosion score at 12 months were analysed according to subgroups based on the RF status (positive or negative), ACPA status (positive or negative), baseline SJC (\<10 or ⩾10), baseline CRP level (\<1.0 or ⩾1.0 mg/dl), RA duration (\<3 or ⩾3 years, this cut-off indicates early RA or not), glucocorticoid use (absence or presence) and baseline ESR (\<28 or ⩾28 mm/h). Two-sided van Elteren stratified rank tests, adjusting for randomized strata (four strata according to the combination of baseline glucocorticoid use and baseline RF), were performed for comparisons between the denosumab groups and placebo group with regard to changes in the radiographic score. In *post hoc* analysis, the proportion of patients without radiographic progression (change in the erosion score from baseline ⩽0.5) and the proportion of patients with rapid erosion progression (change in the erosion score from baseline ⩾3.0 or ⩾5.0) among patients in risk factor subgroups were analysed using Fisher's exact test.

Efficacy endpoints were analysed using the full analysis set that included all randomized patients who received at least one dose of denosumab or placebo and had a baseline radiographic score, as well as at least one post-baseline radiographic score. Missing values for the radiographic scores were imputed using linear extrapolation/interpolation. All statistical analyses were performed using SAS software (release 9.2; SAS Institute, Inc., Cary, NC, USA). The significance level was set at 0.05.

Results
=======

Baseline characteristics and patient disposition
------------------------------------------------

The study included 340 RA patients. Baseline demographics and characteristics were generally comparable between the treatment groups \[[@key416-B9]\].

The mean ([s]{.smallcaps}.[d]{.smallcaps}.) patient ages were 57.0 (10.57) years in the placebo group, 54.4 (10.57) years in the Q6M group, 52.0 (11.65) years in the Q3M group and 54.6 (10.51) years in the Q2M group. However, the proportion of female patients was slightly higher in the placebo group (86.4%) than in the other groups (76.5% in the Q6M group, 72.0% in the Q3M group and 77.6% in the Q2M group).

Radiographic progression
------------------------

Denosumab significantly inhibited the progression of bone erosion at 12 months when compared with the progression on placebo treatment in the overall population of the DRIVE study. The mean changes in the modified Sharp erosion score at 12 months from baseline in the placebo, Q6M, Q3M and Q2M groups were 0.99, 0.27 (*P* = 0.0082 *vs* placebo), 0.14 (*P* = 0.0036) and 0.09 (*P* \< 0.0001), respectively \[[@key416-B9]\].

The score change was greater among RF-positive patients than among RF-negative patients in the placebo group. On the other hand, the difference in the score change between RF-positive and RF-negative patients was less pronounced in the denosumab groups ([Fig. 1A and B](#key416-F1){ref-type="fig"}). A similar tendency was noted for ACPA ([Fig. 1C and D](#key416-F1){ref-type="fig"}).

![Mean change in modified Sharp erosion score from baseline to 12 months in the subgroups\
(**A**) RF-positive subgroup, (**B**) RF-negative subgroup, (**C**) ACPA-positive subgroup and (**D**) ACPA-negative subgroup. The means ± [s]{.smallcaps}.[e]{.smallcaps}.[m]{.smallcaps}. are presented. *P*-values were calculated using the two-sided van Elteren stratified rank test adjusted for randomized strata (four strata according to the combination of baseline glucocorticoid use and baseline RF) *vs* placebo. Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every 3 months; Q6M: denosumab 60 mg every 6 months.](key416f1){#key416-F1}

Changes in the modified Sharp erosion score were numerically smaller among RF-positive patients in all denosumab groups than in the placebo group ([Fig. 1A](#key416-F1){ref-type="fig"} and [Table 1](#key416-T1){ref-type="table"}). The difference between the placebo and Q3M or Q2M groups was statistically significant; however, the difference between the placebo and Q6M groups was not significant. Similarly, the changes were numerically and significantly smaller among ACPA-positive patients in all denosumab groups than in the placebo group ([Fig. 1C](#key416-F1){ref-type="fig"} and [Table 1](#key416-T1){ref-type="table"}). Changes in the bone erosion score among denosumab-treated patients decreased dose-dependently in the RF- and ACPA-positive subgroups. These results are consistent with the primary endpoint in the overall population \[the mean changes in the bone erosion score in the placebo, Q6M, Q3M and Q2M groups were 0.99 (95% CI 0.42, 1.56), 0.27 (0.06, 0.48, *P* = 0.0082 *vs* placebo), 0.14 (0.02, 0.26, *P* = 0.0036) and 0.09 (−0.24, 0.41, *P* \< 0.0001), respectively\].

###### 

Changes in erosion score from baseline to 12 months, according to RF and ACPA status

                                                                             Denosumab                            
  ------------------------------------------------- ------------------- -------------------- -------------------- --------------------
  RF status                                                                                                       
      Positive                                                                                                    
          *n*                                               60                   59                   56                   57
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.18 (3.08)         0.25 (0.73)          0.21 (0.55)          0.15 (1.83)
          Median (Q1, Q3)                            0.00 (0.00, 1.00)   0.000 (0.00, 0.50)   0.000 (0.00, 0.00)   0.000 (0.00, 0.00)
          *P*-value                                         --                 0.0601               0.0422               0.0010
      Negative                                                                                                    
          *n*                                               28                   26                   26                   28
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.59 (1.53)         0.31 (1.41)          −0.02 (0.46)         −0.05 (0.44)
          Median (Q1, Q3)                            0.00 (0.00, 0.50)   0.00 (0.00, 0.00)    0.00 (0.00, 0.00)    0.00 (0.00, 0.00)
          *P*-value                                         --                 0.0827               0.0631               0.0332
  ACPA status                                                                                                     
      Positive                                                                                                    
          *n*                                               66                   70                   64                   65
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.30 (3.04)         0.26 (0.75)          0.16 (0.57)          0.09 (1.73)
          Median (Q1, Q3)                            0.00 (0.00, 1.50)   0.00 (0.00, 0.00)    0.00 (0.00, 0.00)    0.00 (0.00, 0.00)
          *P*-value                                         --                 0.0142               0.0058              \<0.0001
      Negative                                                                                                    
          *n*                                               22                   15                   18                   20
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.07 (0.23)         0.33 (1.73)          0.08 (0.39)          0.08 (0.37)
          Median (Q1, Q3)                            0.00 (0.00, 0.00)   0.00 (0.00, 0.00)    0.00 (0.00, 0.00)    0.00 (0.00, 0.00)
          *P*-value                                         --                 0.2748               0.7166               0.8939

The erosion score was assessed using the van der Heijde modified Sharp method. *P*-values were calculated using the two-sided van Elteren stratified rank test adjusted for randomized strata (four strata according to the combination of baseline glucocorticoid use and baseline RF) *vs* placebo. Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every 3 months; Q6M: denosumab 60 mg every 6 months; *N*: number of patients who received ≥1 dose of the investigational product and had baseline measurement and at least one post-baseline measurement of the radiographic score; *n*: number of patients in the subgroup; Q1, Q3: quartile 1, 3.

On the other hand, the difference in the score between the placebo group and the Q6M, Q3M or Q2M group was numerically lower among RF-negative patients than among RF-positive patients, while a significant difference was observed for only the Q2M group ([Fig. 1B](#key416-F1){ref-type="fig"} and [Table 1](#key416-T1){ref-type="table"}). Additionally, among ACPA-negative patients, no numerical or significant differences were observed between the placebo and denosumab groups ([Fig. 1D](#key416-F1){ref-type="fig"} and [Table 1](#key416-T1){ref-type="table"}).

The proportion of patients with rapid erosion progression (change in erosion score ⩾3 or ⩾5) was larger among RF-positive patients than among RF-negative patients in the placebo group ([Table 2](#key416-T2){ref-type="table"}). The proportion decreased in the denosumab groups, regardless of the baseline RF status; however, statistical significance was observed only for erosion score ⩾3 in the RF-positive subgroup. With regard to the subgroups according to the baseline ACPA status, only ACPA-positive patients in the placebo group showed rapid erosion progression. The proportion of patients with a change in erosion score ⩾3 was significantly lower in the denosumab groups than in the placebo group ([Table 2](#key416-T2){ref-type="table"}). The cumulative probability plots of changes in the erosion score showed that the proportion of patients without radiographic progression was quantitatively larger in all denosumab groups than in the placebo group among the RF-positive, RF-negative and ACPA-positive subgroups, but not the ACPA-negative subgroup ([Fig. 2](#key416-F2){ref-type="fig"}).

###### 

Proportion of patients with rapid erosion progression within the subgroups (RF and ACPA status)

                                  Change in erosion score ≥3   Change in erosion score ≥5            
  ------------------------------ ---------------------------- ---------------------------- --------- --------
  RF status                                                                                          
      Positive                                                                                       
          Placebo (*N* = 60)               8 (13.3)                        --               4 (6.7)     --
          60 mg Q6M (*N* = 59)             0 (0.0)                       0.0061             0 (0.0)   0.1187
          60 mg Q3M (*N* = 56)             0 (0.0)                       0.0063             0 (0.0)   0.1194
          60 mg Q2M (*N* = 57)             1 (1.8)                       0.0325             1 (1.8)   0.3649
      Negative                                                                                       
          Placebo (*N* = 28)               3 (10.7)                        --               1 (3.6)     --
          60 mg Q6M (*N* = 26)             2 (7.7)                       1.0000             1 (3.8)   1.0000
          60 mg Q3M (*N* = 26)             0 (0.0)                       0.2369             0 (0.0)   1.0000
          60 mg Q2M (*N* = 28)             0 (0.0)                       0.2364             0 (0.0)   1.0000
  ACPA status                                                                                        
      Positive                                                                                       
      Placebo (*N* = 66)                  11 (16.7)                        --               5 (7.6)     --
          60 mg Q6M (*N* = 70)             1 (1.4)                       0.0018             0 (0.0)   0.0248
          60 mg Q3M (*N* = 64)             0 (0.0)                       0.0006             0 (0.0)   0.0579
          60 mg Q2M (*N* = 65)             1 (1.5)                       0.0043             1 (1.5)   0.2079
      Negative                                                                                       
          Placebo (*N* = 22)               0 (0.0)                         --               0 (0.0)     --
          60 mg Q6M (*N* = 15)             1 (6.7)                       0.4054             1 (6.7)   0.4054
          60 mg Q3M (*N* = 18)             0 (0.0)                         --               0 (0.0)     --
          60 mg Q2M (*N* = 20)             0 (0.0)                         --               0 (0.0)     --

*P*-values were calculated using Fisher's exact test. *N*: number of patients who received ≥1 dose of the investigational product and had baseline measurement and at least one post-baseline measurement of the radiographic score in the subgroup; *n*: number of patients with an erosion score ≥3 or ≥5.

![Cumulative probability plot of the change from baseline to 12 months in the subgroups\
(**A**) RF-positive subgroup, (**B**) RF-negative subgroup, (**C**) ACPA-positive subgroup and (**D**) ACPA-negative subgroup. The figures in the plots are the proportions of patients without erosion progression (Δ erosion score ≤0.5). Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every 3 months; Q6M: denosumab 60 mg every 6 months.](key416f2){#key416-F2}

Furthermore, we performed subgroup analysis involving other potential prognostic factors. Changes in the bone erosion score were smaller in the denosumab groups than in the placebo group among all subgroups that were based on factors such as baseline SJC, baseline CRP level, RA duration and baseline ESR status ([Table 3](#key416-T3){ref-type="table"} and [supplementary Figs S1--S4](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). A numerically great change in the erosion scores of patients in the placebo group was observed in the patients with a baseline SJC ⩾10, baseline CRP level ⩾1.0 mg/dl, RA duration ⩾3 years or baseline ESR ⩾28 mm/h. However, significant differences were only observed in the Q3M and Q2M groups, among patients with a baseline SJC ⩾10 and in the Q2M group among those with a baseline ESR ⩾28 mm/h. With regard to the counterpart subgroups (i.e. baseline SJC \<10, baseline CRP level \<1.0 mg/dl, RA duration \<3 years and baseline ESR \<28 mm/h) that showed a small change (around 0.5) in the bone erosion score in the placebo group, significant decreases in the score were observed in all denosumab groups, excluding the Q6M group, among patients with an RA duration \<3 years.

###### 

Changes in the erosion score from baseline to 12 months according to other risk factors

                                                                             Denosumab                          
  ------------------------------------------------- ------------------- ------------------- ------------------- --------------------
  Baseline SJC                                                                                                  
      ≥10                                                                                                       
          *n*                                               39                  27                  42                   40
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.50 (3.61)         0.71 (1.40)         0.25 (0.64)         0.03 (0.53)
          Median (Q1, Q3)                            0.00 (0.00, 1.00)   0.00 (0.00, 1.50)   0.00 (0.00, 0.50)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.4747               0.038               0.0009
      \<10                                                                                                      
          *n*                                               49                  58                  40                   45
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.59 (1.55)         0.07 (0.63)         0.03 (0.37)         0.14 (2.04)
          Median (Q1, Q3)                            0.00 (0.00, 0.50)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.0228              0.0479               0.0186
  Baseline CRP                                                                                                  
      ≥1.0 mg/dl                                                                                                
          *n*                                               21                  13                  13                   11
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.69 (4.35)         0.89 (1.89)         0.42 (0.61)         0.32 (1.03)
          Median (Q1, Q3)                            0.00 (0.00, 2.00)   0.00 (0.00, 1.50)   0.00 (0.00, 1.00)   0.00 (−0.50, 1.50)
          *P*-value                                         --                0.6656              0.6310               0.3966
      \<1.0 mg/dl                                                                                               
          *n*                                               67                  72                  69                   74
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.77 (1.90)         0.16 (0.67)         0.09 (0.51)         0.05 (1.58)
          Median (Q1, Q3)                            0.00 (0.00, 1.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.0213              0.0078               0.0002
  Duration of RA                                                                                                
      ≥3 years                                                                                                  
          *n*                                               28                  26                  24                   25
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.65 (4.20)         0.03 (0.64)         0.04 (0.55)         0.59 (2.63)
          Median (Q1, Q3)                            0.00 (0.00, 1.75)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.1549              0.1746               0.1702
      \<3 years                                                                                                 
          *n*                                               60                  59                  58                   60
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.68 (1.51)         0.37 (1.09)         0.18 (0.53)         −0.13 (0.57)
          Median (Q1, Q3)                            0.00 (0.00, 0.75)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.1036              0.0298              \<0.0001
  Baseline ESR                                                                                                  
      ≥28 mm/h                                                                                                  
          *n*                                               33                  23                  26                   29
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.88 (3.97)         0.81 (1.60)         0.42 (0.64)         0.03 (0.77)
          Median (Q1, Q3)                            0.00 (0.00, 2.00)   0.00 (0.00, 1.50)   0.00 (0.00, 1.00)   0.00 (0.00, 0.50)
          *P*-value                                         --                0.4237              0.2920               0.0144
      \<28 mm/h                                                                                                 
          *n*                                               55                  62                  56                   56
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.46 (1.23)         0.07 (0.50)         0.01 (0.42)         0.11 (1.80)
          Median (Q1, Q3)                            0.00 (0.00, 0.50)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.0173              0.0081               0.0034
  Glucocorticoid use                                                                                            
      Present                                                                                                   
          *n*                                               37                  36                  37                   37
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       1.37 (3.74)         0.33 (1.24)         0.23 (0.57)         −0.07 (0.73)
          Median (Q1, Q3)                            0.00 (0.00, 0.50)   0.00 (0.00, 0.00)   0.00 (0.00, 0.50)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.1885              0.5262               0.0072
      Absent                                                                                                    
          *n*                                               51                  49                  45                   48
          Mean ([s]{.smallcaps}.[d]{.smallcaps}.)       0.72 (1.51)         0.22 (0.74)         0.07 (0.50)         0.20 (1.92)
          Median (Q1, Q3)                            0.00 (0.00, 1.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)   0.00 (0.00, 0.00)
          *P*-value                                         --                0.0307              0.0023               0.0041

The erosion score was assessed using the van der Heijde modified Sharp method. *P*-values were calculated using the two-sided van Elteren stratified rank test adjusted for randomized strata (four strata according to the combination of baseline glucocorticoid use and baseline RF) *vs* placebo. Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every 3 months; Q6M: denosumab 60 mg every 6 months; *N*: number of patients who received ≥1 dose of the investigational product and had baseline measurement and at least one post-baseline measurement of the radiographic score; *n*: number of patients in the subgroup; SJC: swollen joint count; Q1, Q3: quartile 1, 3.

In addition, subgroup analysis involving glucocorticoid use (one of the stratification factors) was performed. In the placebo group, bone erosion progression was greater among patients with basal glucocorticoid use than among those without glucocorticoid use ([Table 3](#key416-T3){ref-type="table"} and [supplementary Fig. S5](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). Denosumab effectively reduced the mean change in the erosion score in both subgroups. Among patients with glucocorticoid use, a significant reduction in the erosion score was observed only in the Q2M group, while among patients in all denosumab groups without glucocorticoid use, a significant reduction was observed.

Discussion
==========

Bone erosion is a central clinical feature of RA and is associated with enhanced osteoclast differentiation stimulated by two essential mediators (M-CSF and RANKL) \[[@key416-B3]\]. Denosumab, an anti-RANKL antibody, was found to be effective for bone erosion; however, it likely has no effect on disease activity \[[@key416-B9], [@key416-B17]\]. In this study, we evaluated the efficacy of denosumab with regard to the progression of bone erosion in patients receiving MTX among subgroups positive for the risk factors of progression, such as RF, ACPA status, baseline SJC and CRP level. The results were generally consistent for the primary endpoint, with regard to the overall population of the DRIVE study. Additionally, the quantitative trend of dose-dependent inhibition in the risk factor subgroups was consistent with the result in the overall population. However, there were differences among the subgroups according to the presence/absence of the risk factors of progression in, not only the placebo group, but also the denosumab groups.

Previous studies have shown that positive RF and ACPA findings are risk factors for bone erosion progression in patients with RA \[[@key416-B11], [@key416-B12]\]. Our results are consistent with these findings. Radiographic progression at 12 months was much greater among RF-positive and ACPA-positive patients than among negative patients, especially in the placebo group. Denosumab showed a potent inhibitory effect on bone erosion in a dose-dependent manner among RF-positive and ACPA-positive patients. Thus, denosumab is considered as a treatment option for RA patients with bone erosion progression, despite a positive RF and/or ACPA status.

The present study also evaluated the efficacy of denosumab in RF-negative and ACPA-negative patients, who may experience only limited progression of joint destruction. Denosumab did not show a clear effect in these patients. Accordingly, these patients do not appear to benefit from denosumab treatment. However, the assessment of negative subgroups involved small sample sizes; thus, the findings should be interpreted with caution. Moreover, the disease activity of patients in this study was lower than that of patients in clinical studies involving other biologics \[[@key416-B18]\]. It is likely that the investigators controlled the disease activity well in this study, as they could adjust the dosage of MTX within approved limits and prescribe salazosulfapyridine and/or bucillamine as needed throughout the study period. Nevertheless, 17.9 and 4.5% of patients experienced ongoing bone erosion (score \>0.5) in the RF-negative and ACPA-negative subgroups of the placebo group, respectively. However, denosumab was shown to reduce this proportion. Previous studies reported that erosion progresses in patients who have not achieved remission, despite control of disease activity with conventional synthetic DMARDs \[[@key416-B21], [@key416-B22]\]. In addition, a substantial proportion of patients treated with MTX monotherapy show rapid radiographic progression despite RF and/or ACPA negativity \[[@key416-B13]\]. Thus, the current prognostic risk factors are not sufficient to identify progressive patients, and it remains unclear whether denosumab is beneficial for RA patients with a low risk for progressive bone erosion.

Denosumab was significantly effective at all assessed doses among patients with a baseline SJC ⩾10, baseline CRP \<1.0 mg/dl, RA duration \<3 years, baseline ESR \<28 mm/h and no glucocorticoid use. However, in contrast to the subgroups with the RF and ACPA status, the changes in bone destruction were smaller among these subgroups in the placebo group. In this study, only RF and glucocorticoid use were stratification factors, while the treatment assigned within these subgroups was balanced for known and unknown prognostic factors. The other subgroups were created *post hoc*, so there may exist an imbalance in the other prognostic factors. Additionally, interactions between the subgroups were not assessed because of the small sample size. Therefore, the statistical results of this study should be interpreted carefully.

The present study had some limitations. First, the treatment duration was relatively short (12 months). Second, the sample size was small, resulting in seemingly underpowered significance analyses in some subgroups. Finally, only a partial *post hoc* analysis was performed (proportions of patients without radiographic progression and rapid radiographic progression in the DRIVE study).

In conclusion, RF and ACPA are poor prognostic factors and denosumab is a potentially useful treatment option for RA patients receiving MTX with these factors. Although denosumab was found to reduce the proportion of progressive patients in the risk factor-negative subgroups, a further clinical trial with an adequate sample size is required to confirm the findings.

Supplementary Material
======================

###### 

Click here for additional data file.
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